Table 2.

Summary of treatment emergent adverse events experienced by at least 10% of subjects, irrespective of causality

TEAEs	Part 1/Cohort 1 (N = 3)	Part 1/Cohort 2 (N = 3)	Part 1/Cohort 3 (N = 3)	Part 1/Cohort 4 (N = 3)	Part 1/Cohort 5 (N = 3)	Part 2/ 24 mg/kg (N = 21)	All Parts at 24 mg/kg (N = 24)	Total (N = 36)
All TEAEs	3 (100.0%)	3 (100.0%)	3 (100.0%)	3 (100.0%)	3 (100.0%)	20 (95.2%)	23 (95.8%)	35 (97.2%)
Fatigue	1 (33.3%)	0	0	1 (33.3%)	1 (33.3%)	8 (38.1%)	9 (37.5%)	11 (30.6%)
Decreased appetite	2 (66.7%)	0	1 (33.3%)	0	0	5 (23.8%)	5 (20.8%)	8 (22.2%)
Nausea	1 (33.3%)	1 (33.3%)	0	1 (33.3%)	0	5 (23.8%)	5 (20.8%)	8 (22.2%)
Anaemia	1 (33.3%)	1 (33.3%)	0	1 (33.3%)	1 (33.3%)	2 (9.5%)	3 (12.5%)	6 (16.7%)
Abdominal distension	1 (33.3%)	0	0	0	0	5 (23.8%)	5 (20.8%)	6 (16.7%)
Vomiting	1 (33.3%)	0	0	1 (33.3%)	1 (33.3%)	3 (14.3%)	4 (16.7%)	6 (16.7%)
Diarrhoea	0	1 (33.3%)	0	0	0	4 (19.0%)	4 (16.7%)	5 (13.9%)
Rash	2 (66.7%)	0	0	0	0	3 (14.3%)	3 (12.5%)	5 (13.9%)
Pyrexia	1 (33.3%)	0	1 (33.3%)	0	0	3 (14.3%)	3 (12.5%)	5 (13.9%)
Abdominal pain	0	1 (33.3%)	0	0	0	3 (14.3%)	3 (12.5%)	4 (11.1%)
Constipation	0	1 (33.3%)	1 (33.3%)	0	0	2 (9.5%)	2 (8.3%)	4 (11.1%)
Back pain	0	1 (33.3%)	0	0	1 (33.3%)	2 (9.5%)	3 (12.5%)	4 (11.1%)
Musculoskeletal pain	1 (33.3%)	1 (33.3%)	0	1 (33.3%)	0	1 (4.8%)	1 (4.2%)	4 (11.1%)
Dyspnoea exertional	0	0	0	1 (33.3%)	0	3 (14.3%)	3 (12.5%)	4 (11.1%)
Pruritus	2 (66.7%)	0	0	0	0	2 (9.5%)	2 (8.3%)	4 (11.1%)

n (%) is shown